raltegravir, Isentress

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: raltegravir

BRAND NAME: Isentress

DRUG CLASS AND MECHANISM: Raltegravir (Isentress) is an antiretroviral medicine approved for the treatment of human immunodeficiency virus (HIV) infection. Raltegravir is an integrase inhibitor similar to elvitegravir (Vitekta) and dolutegravir (Tivicay). Raltegravir slows the spread of HIV infection by blocking the HIV integrase enzyme required for virus multiplication. To improve the chance of fighting HIV-1 infection, raltegravir must be taken with other HIV medicines. Although raltegravir does not cure HIV or AIDS, continuous HIV treatment with raltegravir can help patients control the infection and decrease their risk of acquiring HIV-related illnesses. Raltegravir helps to improve the immune system by increasing the number of white blood cells called CD4+ (T) cells, and consequently reduce the risk of death or getting opportunistic infections that can happen when the immune system is weak. Raltegravir was initially approved by the FDA in October 2007.

Medically Reviewed by a Doctor on 2/23/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index

Health Solutions From Our Sponsors